Business Description
Kala Bio Inc
NAICS : 541714
SIC : 2836
ISIN : US4831191030
Total Employee Number:
6Description
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 2.78 | |||||
Debt-to-EBITDA | -1.74 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 51.2 | |||||
3-Year EPS without NRI Growth Rate | 57.7 | |||||
3-Year FCF Growth Rate | 57.9 | |||||
3-Year Book Growth Rate | -71.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 89.59 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 99.09 | |||||
9-Day RSI | 98.33 | |||||
14-Day RSI | 97.32 | |||||
3-1 Month Momentum % | 2051.9 | |||||
6-1 Month Momentum % | 550.1 | |||||
12-1 Month Momentum % | -33.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.91 | |||||
Quick Ratio | 7.91 | |||||
Cash Ratio | 5.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -154 | |||||
Shareholder Yield % | 29.6 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -847.59 | |||||
ROA % | -74.94 | |||||
ROIC % | -235.1 | |||||
3-Year ROIIC % | -235.46 | |||||
ROC (Joel Greenblatt) % | -1000.23 | |||||
ROCE % | -157.33 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.47 | |||||
Price-to-Tangible-Book | 1.47 | |||||
EV-to-EBIT | -0.39 | |||||
EV-to-EBITDA | -0.4 | |||||
EV-to-Forward-Revenue | 0.24 | |||||
EV-to-FCF | -0.32 | |||||
| Price-to-Net-Current-Asset-Value | 1.47 | |||||
| Price-to-Net-Cash | 2.18 | |||||
Earnings Yield (Greenblatt) % | -255.19 | |||||
FCF Yield % | -180.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kala Bio Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -124.713 | ||
| Beta | 2.0896 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 13.61 | ||
| Volatility % | 145.48 | ||
| 14-Day RSI | 97.32 | ||
| 14-Day ATR (€) | 0.00659 | ||
| 20-Day SMA (€) | 3.4 | ||
| 12-1 Month Momentum % | -33.33 | ||
| 52-Week Range (€) | 0.0686 - 16.99 | ||
| Shares Outstanding (Mil) | 18.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kala Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kala Bio Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-19 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 20 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 3.40 (+0.00%) | ||
| 0.02:1 Stock Split | 2026-05-11 | 3.40 (+0.00%) | ||
| Annual report for 2025 | 2026-04-15 | 0.18 (-6.12%) | ||
| General meeting for 2025 | 2026-01-30 11:00 | 0.46 (-2.93%) | ||
| Third quarter earnings results for 2025 | 2025-11-19 | 0.56 (-1.91%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-10 14:00 | 12.16 (+0.50%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 6.25 (+1.30%) | ||
| Kala Bio Inc KPI-012 for Rare Ocular Surface Disease | 2025-07-16 16:00 | 4.95 (+0.28%) |
Show
Entries
Kala Bio Inc Frequently Asked Questions
What is Kala Bio Inc(FRA:27F)'s stock price today?
The current price of FRA:27F is €3.40. The 52 week high of FRA:27F is €16.99 and 52 week low is €0.07.
When is next earnings date of Kala Bio Inc(FRA:27F)?
The next earnings date of Kala Bio Inc(FRA:27F) is 2026-08-07 Est..
Does Kala Bio Inc(FRA:27F) pay dividends? If so, how much?
Kala Bio Inc(FRA:27F) does not pay dividend.
Press Release
Articles on Kala Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers